Polaryx Therapeutics PLYX
NASDAQ PLYX
$2.07 -0.07 (-3.27%)
At close: Aug 21, 2026 · 4:00 PM EDT

Polaryx Therapeutics (PLYX) Income from Continuing Operations (2025 - 2026)

Polaryx Therapeutics (PLYX) posted quarterly Income from Continuing Operations of 1958000.0 for Q1 2026, up 61.24% year-over-year from 1214315.74 in Q1 2025, and up 61.24% quarter-over-quarter from 5052000.0 in Q1 2025.

Polaryx Therapeutics (PLYX) Income from Continuing Operations (2025 - 2026) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Income from Continuing Operations for 2 consecutive years, with 1958000.0 the latest figure, recorded in Q1 2026.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 482.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 Polaryx Therapeutics 99.45 Mn 87.91 Mn - -1.38 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.38 Mn
Mar 31, 2026 -1.96 Mn
Mar 31, 2025 -5.05 Mn